Boiron Confirms Eligibility for PEA-PME
Boiron Laboratories have announced that their shares meet the eligibility criteria for the equity savings plan aimed at small and medium-sized enterprises and intermediate-sized enterprises. The group's shares can now be included in PEA-PME accounts, according to the press release.
Eligibility Criteria Met
The pharmaceutical group has confirmed that it meets the eligibility conditions for the PEA-PME scheme as defined by Article L. 221-32-2 of the Monetary and Financial Code. Under this regulatory framework, a company whose shares are admitted to trading on a regulated market can benefit from this eligibility if its market capitalization is less than two billion euros, or has been at the close of at least one of the four calendar years preceding the reference year. Boiron's shares, identified by the ISIN code FR0000061129, are therefore integrable into PEA-PME accounts, the company indicates. This eligibility allows individual investors to benefit from the advantageous tax framework of the PEA-PME by including the laboratory's shares in their portfolio. The group specifies that this qualification concerns all of its shares admitted to trading on Euronext Paris.
Upcoming Financial Event
The laboratory has also communicated about its next financial event. The publication of the annual results for the fiscal year 2025 is scheduled for April 2, 2026, at the close of the Paris Stock Exchange. This communication will take place within the usual framework of the group's financial information dissemination. Investors and analysts will be able to review the performances achieved by the group over the past year. The company reminds that all its financial information, as well as a glossary, are available on its website dedicated to investor relations. For any questions related to financial information, the group provides dedicated contacts for shareholders and finance professionals.
